

VIET A	TRANSPORT				_				
	ATION DISCLOS	SURE	Application No. 10/790,498			Inventor Alexandros Makriyannis et al			
CITATIO APPLICA				Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors					
//	11-5-2004			ng Date /01/2004		Group Art Unit 1614	Docket No. UCONAP/226/US		US
_	UN	ITED S	STA	TES PATE	ENT	DOCUMENTS			
Examiner Initial-date	Document No.	Date	е			Name			Class
/KS/	2002/0119972	8/29/	02	Leftheris 01/58869		(appears equ	ivalent to W)	1
/KS/	5925768	7/20/	99						
/KS/	5939429	8/17/	99	Kunos et					514
	FOREIGN PATENT DOCUMENTS								
Examiner Initial-date	Document No.	Date)	Country	 	Name		Tr	anslation
/KS/	EP 0 576 357	´12/29/	93	Barth et al (including English bibliography and abstract)		nc)		
/KS/	WO 97/21682 V	6/19/9	7	Int'l Barth et al (including bibliography, appears equivalent to US5925768)		ears	nc		
/KS/	WO 01/58869	8/16/0)1	Int'l	Left equ	theris et al (appears livalent to 2002/011997)		in Er	nglish
	OTHER D	CUM	ENT	S (Including)		Title, Date, Pertinent	Banca Stall	İ	
Examiner	T			• (Including F	tutnor,	Tille, Date, Pertinent	Pages, Etc.)		
Initial-date									
Meschler, J. P., Kraichely, D. M., Wilken, G. H., Howlett, A. C.; "Inverse Agonist Properties of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCL (SR141716A) and 1-(2-Chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic Acid Phenylamide (CP-272871) for the CB1 Cannabinoid Receptor"; Biochemical Pharmacology; (2000); vol. 60; no. 9; 1315-1322.									
/KS/	dbilo, O., Dero peripheral can expression in h vol. 448; no. 2	cq, J., nabino numan	Seg id re pro	ui, M., Le eceptor CE myelocytic	Fur, 0	G., Casellas, I luces MCP-1	P.; "Stimulation and IL-8 gen	on o	of

vol. 448; no. 21848; 273-277

INFORM	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros Makriyannis et al				
CITATIO		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors					
_		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US			
/KS/	Quere, L., Boigegrain, R., Jeanjean, F., Gully, D., Evrard, G., Durant, F.; "Structural requirements of non-peptide neurotensin receptor antagonists"; J. Chem Soc., Perkin Trans. 2, (1996); 2639-2646.						
/KS/	Griffin, G., Wray, E. J., Tao, Q., McAllister, S. D., Rorrer, W. K., Aung, M., Martin, B. R., Abood, M. E.; "Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system"; European Journal of Pharmacology; (1999); vol. 377; 117-125.						
/KS/	SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT for application no. 02 76 8751, pages 1-2,						
Examiner	/Kamal Saeed/	Date Considered	05/28/2007				
	/Kamal Saeed/			MPEP §609; Draw line through			

citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

G:\AYR saved docs\Filing Docs\Uconap\uconap226us cip of uconap197pc\10-04 IDS.doc



INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Application No. Inventor 10/790,498 Alexandros Makriyannis et al

Title

Novel Pyrazole Analogs Acting on Cannabinoid Receptors

mailed 1-6-05 Filing Date 03/01/2004

Date Group Art Unit 01/2004 1614 Docket No. UCONAP/226/US

UNITED STATES PATENT DOCUMENTS

Examiner Initial-date	Document No.	Date	Name	Class
/KS/	09/600786	11/24/99	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 00/32200 enclosed herewith)	
/KS/	09/698,071	10/30/00	Fride et al, (copy not included, this is the parent application for US Publication No. 2002/0173528, enclosed herewith)	
/KS/	09/701989	6/9/99	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 99/64389 enclosed herewith)	
/KS/	10/110865	10/18/00	*1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith)	
/KS/	10/110830	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith)	
/KS/	10/110812	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith)	

	ATION DISCLOS	URE	Application No. 10/790,498		Inventor Alexandros Makriyannis et al		
CITATIO APPLICA			Title Novel Pyrazol	Title Novel Pyrazole Analogs Acting on Cannabinoid Re		Receptors	
			Filing Date 03/01/2004			Docket No. UCONAP/2	26/US
/KS/	10/110862	10/1	10/18/00		Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith)		
/KS/	10/111059	10/1	8/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith)			
/KS/	10/647544	8/25	/03	Mak	criyannis et al		
/KS/	10/899,191	7/26	/04	Mak	criyannis et al		
/KS/	2002/0173528	11/2	1/02	Fride et al			
/KS/	2003/0120094	6/26	03	Mak	Makriyannis et al		
/KS/	2003/0149082	8/7/0)3	Makriyannis et al			
/KS/	2004/0077649	4/22	/04	Mak	riyannis et al		
/KS/	2004/0077851	4/22	04		riyannis et al		
/KS/	2004/0087590	5/6/0	4	Mak	Makriyannis et al		
/KS/	2004/0192667	3/1/0	4	Makriyannis et al			
/KS/	2004/0236101	10/2	3/02	inclu Nati App	criyannis et al uded, this is th ional Phase of lication publis 35005 enclose	e U.S. the Int'l hed as WO	
/KS/	2004/0236116	7/11/02		Mak inclu Nati App 03/0	criyannis et al auded, this is the conal Phase of clication publishments (105960 enclosewith)	(copy not le U.S. the Int'l hed as WO	
/KS/	3041343	6/26/	62	*1*,	Jucker et al		
/KS/	3465024	9/2/6	9	Brov	wnstein et al		
/KS/	3573327	3/30/	71	Miya	ano		
/KS/	3577458	5/4/7			wnstein et al		
/KS/	3656906	4/18/	72	Bulle	ock		
/KS/	3838131 .	9/24/		Gau	thier		
/KS/	3886184	5/27/			sumoto et al		
/KS/	3897306	7/29/	75	Vidio	C		

INFORM	ATION DISCLOS	URE	Application No. 10/790,498		Inventor Alexandros Makriyannis et al			
CITATIO			Title		logs Acting on	Connobinoid I	Pagantara	
APPLICA	ATION		•	——	logs Acting on			
 			Filing Date 03/01/2004	·	Group Art Unit 1614	Docket No. UCONAP/2	on No. ONAP/226/US	
/KS/	3915996	10/2	8/75	Wrig	ght			
/KS/	3928598	12/2	3/75	Arch	ner			
/KS/	3944673	3/16	76	Arch	ner			
/KS/	3946029	3/23	776	Des	camps et al			
/KS/	3953603	4/27	76	Arch	ner			
7KS/	4036857	7/19/	77	Raz	dan et al			
/KS/		10/1	B <i>1</i> 77	Blar	nchard et al			
/KS/	4087545	5/2/7	'8	Arch	ner et al	· · · · · · · · · · · · · · · · · · ·		
/KS/		5/2/7	'8	Arch	ner et al			
/KS/	4087547	5/2/7	8	Arch	ner et al			
/KS/	4088777	5/9/7	8	Arch	ner et al			
/KS/	4102902	7/25/	78	Arch	ner et al			
/KS/	4152450	5/1/7	9	Day	et al			
/KS/	4171315	10/10	6/79	Rya	n et al			
/KS/	4176233	11/2	7/79	Arch	ner et al			
/KS/	4179517	12/18	3/79	Mechoulam				
7KS	4188495	2/12/	/80	Alth	uis et al			
/KS/	4208351	6/17/	80	Arch	ner et al			
/KS/	4278603	7/14/	' 81	Tha	kkar et al			
/KS/	4282248	8/4/8	1	Mec	houlam et al			
/KS/	4382943	5/10/	83	Win	ter et al			
/KS/	4395560	7/26/	83	Rya	n			
/KS/		2/5/8	5	Nels	on			
/KS/	4550214	10/29	9/85	Meh	ta			
/KS/	4758597	7/19/	88	Mar	tin et al			
/KS/	4812457	3/14/	89	Narı	umiya			
/KS/	4876276	10/24	1/89	Mec	houlam			
/KS/	4885295	12/5/	89	Bell	et al			
/KS/	5053548	10/1/	91 .	Tana	aka et al			
/KS/	5068234	11/26	5/9 <u>1</u>	D'Ar	nbra et al			
/KS/	5147876	9/15/	92	Mizu	ichi et al			
/KS/	5223510	6/29/	93	Gub	in et al			
/KS/	5284867	2/8/9	4	Kloo	<u> </u>	·		
/KS/	5324737	6/28/	94	D'Ar	nbra et al			
/KS/	5434295	7/18/	95	Mec	houlam et al			
/KS/	5440052	8/8/9			riyannis et al			
/KS/	5462960	10/31	/95	*1* E	Barth et al			

INFORM	ATION DISCLOS	URE	Application No. 10/790,498		Inventor Alexandros Makriyannis et al		
CITATION APPLICA	N IN AN		Title Novel Pyrazol	e Ana	logs Acting on	Cannabinoid Receptors	
 			Filing Date 03/01/2004		Group Art Unit Docket No. 1614 UCONAP/226/US		
/KS/	5489580	2/6/9	96	Mak	Makriyannis et al		
/KS/	5521215	5/28	/96	Med	houlam		
	5532237	7/2/9	96	Gall	ant et al		
7KS/	5538993	7/23	/96	Med	houlam		
/KS/	5576436	11/1	9/96	McC	Cabe et al		
/KS/	5605906	2/25	/97	Lau			
/KS/	5607933	3/4/9	97	D'A	mbra et al		
/KS/	5618955	4/8/9	7	*1*	Mechoulam e	et al	
/KS/	5624941	4/29	/97	*1*	Barth et al		
/KS/	5631297	5/20	/97	Pate	e et al		
/KS/	5635530	6/3/9	6/3/97		Mechoulam		
/KS/	5688825	11/1	11/18/97		riyannis et al		
/KS/	5747524	5/5/9	8	*1*	Cullinan et al		
/KS/	5744459			Mak	riyannis et al		
	5804601	9/8/9	8	Kato et al (appears			
/KS/				equivalent to EP0737671)			
/KS/	5817651	10/6	/98	D'Ambra et al			
/KS/	5872148	2/16	/99	Makriyannis et al			
/KS/	5874459	2/23	/99	Mak	riyannis et al		
/KS/	5925628	7/20	/99	Lee	et al		
/KS/	5932610	8/3/9	9	Sho	hami et al		
/KS/	5948777	9/7/9	9	*1*	Bender et al		
/KS/	6013648	1/11/	/00		aldi et al (appe ivalent to FR2		
/KS/	6028084	2/22	/00		Barth et al	·	
/KS/	6096740	9/1/0	00	Med	houlam		
/KS/	6127399	10/3	/00	*1* `	Yuan		
/KS/	6166066	12/2	6/00	Mak	riyannis et al		
/KS/	6284788	10/4/	<i>(</i> 01	Mitte	endorf et al (a valent to EP8		
/KS/	6391909	5/21/	02		riyannis et al		
/KS/	6579900	6/17/		Makriyannis et al			
/KS/	6610737	8/26/	/ 03	_	zon et al		

	INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/790,498 Title		Inventor Alexandros Makriyannis et al			
APPLICA	ATION	·	Filing			logs Acting on Group Art Unit 1614	Cannabinoid Docket No. UCONAP/2	
Examiner	Document No.	FORE Da		PATENT Country	DOC	UMENTS Name		Translation
initial-date							·	Translation
/KS/	EP0276732	8/3/8		EP	-	man La Roch		
/KS/	EP0444451	9/4/9	01	EP *1 bi ce		*1* Sterling Drug (English bibliography, abstract and cover page, appears equivalent to US5068234 which is also cited)		
/KS/	EP0471609	6/29	/93	EP	Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510)			
/KS/	EP0737671	10/1	6/96	EP	Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)		·	
/KS/	EP0860168	9/4/0)1	EP	fron Eng appe	endorf et al, in t page only (ir lish bibliograp ears equivaler 284788)	icluding hy,	
/KS/	FR2240003	5/27/		FR	Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184)			
/KS/	FR2735774	1/11/	00	FR				
/KS/	GB2027021A	2/13/	80					
/KS/	IL1995-113228	9/22/	99	IL	R. Mechoulam et al (abstract only)			

1	ATION DISCLOS	URE		cation No. '90,498		Inventor Alexandros I	os Makriyannis et al	
CITATIO APPLICA			Title Nove	Title Novel Pyrazole Analogs Acting on Cannabinoid Recep			Receptors	
			Filing Date 03/01/2004			Group Art Unit 1614	Docket No. UCONAP/2	26/US
/KS/	JP2304080	12/1	7/90	JP	Jap	Nakayama Hajime et al, in Japanese (including English bibliography and abstract)		
/KS/	JP57098228	6/18	/82	JP	(incl	la et al, in Jap luding English lography and		
/KS/	WO 00/32200	6/8/0	0		Mak	riyannis et al,	in English	
/KS/	WO 01/28329	4/26	/01			riyannis et al,		
/KS/	WO 01/28497	4/26	/01		Mak	riyannis et al,	in English	
/KS/	WO 01/28498	4/26	/01		Mak	riyannis et al,	in English	
/KS/	WO 01/28557	4/26			Makriyannis et al, in English			
/KS/	WO 01/29007	4/26	01			Makriyannis (Ilish	et al, in	
/KS/	WO 01/32169	5/10/	/ 01		Frid	e et al, in Eng	lish	
/KS/	WO 02/058636	8/1/0	2		*1* Eng	Makriyannis (lish	et al, in	
/KS/	WO 02/060447	8/8/0	2		Mak	riyannis et al,	in English	
/KS/	WO 03/005960	1/23/	′ 03			riyannis et al,		
/KS/	WO 03/035005	5/1/0	3		*1* I Eng	Makriyannis (lish	et al, in	
/KS/	WO 03/063758	8/7/0	3			zon et al, in E	nglish	
/KS/	WO 03/064359	8/7/0	3			zon et al, in E		
/KS/	WO 94/12466	6/9/9	4			houlam et al		English
/KS/	WO 97/00860	1/9/9	7		(incl biblic appe	aldi et al, in Frouding English ography and a ears equivaler 013648)	abstract,	
/KS/	WO 99/57106	11/1	1/99			riyannis et al,	in English	
/KS/	WO 99/57107	11/11				riyannis et al,		
/KS/	WO 99/64389	12/16				riyannis et al,		

	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al		
CITATION APPLICA		Title Novel Pyrazole Ana	alogs Acting on	Cannabinoid Receptors		
	·	Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US		
		OTHER DOCUME	NTS			
Examiner Initial - date	(Include Author, Title,	Publication Date,	Pertinent Pag	es, Etc.)		
/KS/	Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; "(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability"; J. Med. Chem.; 37(12); 1889-1893; 1994; CODEN: JMCMAR; ISSN: 0022-2623; XP002040932					
/KS/	Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768					
/KS/	*** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977)					
/KS/	Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. (abstract only)					
/KS/	Barnett-Norris et al; "I anandamide, "; J.	•	•			
/KS/	Beak, P.; and Brown, Ortho Lithiation, J. Or	R A., The Tertiary	Amide as an			
/KS/	Belgaonkar et al; "syn 4; 336-338; 1975 (abs	thesius of isocoum		J. Chem; vol. 13; no.		
/KS/	Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition"; Science; vol. 277; 1094-1097; 1997					
/KS/	Beltramo M., Stella N. "Identification and Fur The Neurosciences In	nctional Role of Hig				
/KS/	Beltramo M., Piomelli Agonist Olvanil"; Euro (abstract only)			oition by the Vanilloide 9); 364(1); 75-78		
/KS/	Berdyshev EV, Canna response. Chem Phys	•	_			
/KS/	response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90 Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors:"; Prostanglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998).					

1	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al			
APPLICA		· ·		Cannabinoid Receptors			
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US			
/KS/	Bodnar, V.N., Lozinsk 1,3,4-oxadiazoles and Khimicheskii Zhurnal only)	1 1,4-dihydro-1,2,4	,5-tetrazines";	•			
/KS/	Bracey, M et al, Struc Terminates Endocann 1796			e Enzyme That 02; 298(5599): 1793-			
/KS/	Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and						
/KS/	Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876. (abstract only)						
/KS/	Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990)						
/KS/		I, Mpzey E et al, "I cient for the cannal	mmunomodu	ation by cannabinoids eceptor"; Eur. J			
/KS/	Burstein et al; "detecti Res. Commun.; vol. 1	76(1); 492 <mark>-4</mark> 97; 19	91 (abstract	only)			
/KS/	Busch-Peterson et al; hydroxyhexahydrocan (1996)						
/KS/				trol of pain initiation by 91. (abstract only)			
/KS/	Calignano A., La Rana "Potentiation of Anano AM404"; Eur. J. Pharn	endogenous cannabinoids"; Nature (1998) 394:277-291. (abstract only) Calignano A., La Rana G., Beltramo, M., Makriyannis A., Piomelli D; "Potentiation of Anandamide Hypotension by the Transport Zinhibitor, AM404"; Eur. J. Pharmacol.; 1997; 337 R1-R2					
/KS/	Calignano A., La Rana "Inhibition of Intestinal Cannabinoid"; Eur. J.	Motility by Ananda Pharmacol.; 1997;	amide, an End 340 R7-R8	logenous			
/KS/		e cannabinoids an	effective and	safe treatment option eview"; BMJ. 2001 Jul			

	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al			
CITATIO APPLICA		Title Novel Pyrazole Ana	logs Acting on	Cannabinoid Receptors			
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US			
/KS/		al; "5'-azido $\Delta 8$ -THC: A Novel Photoaffinity Label for the or"; J. Med. Chem., 35, 3076 - 3079 (1992)					
/KS/	Charalambous A. et a Pharmacol. Biochem.	l; "Pharmacologica Behav.; vol. 40; no	l evaluation o . 3; 509-512;	of halogenated"; 1991			
/KS/	Cheng et al; "Relation concentration of Inhib Enzymatic Reaction"; (abstract only)	itor which causes 5	0% Inhibition	ı (IC50) óf an			
/KS/	Cherest M., Luscindi X anhydride on the lithiu	ım nitronate salt of	2-phenylnitro	ethane";			
/KS/	Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989						
/KS/	Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. (abstract only)						
/KS/	Compton D.R. et al; "F Cannabinoid Analogs: Pharmacol. Exp. Ther	Classification as (Cannabimime	tic Agents"; J.			
/KS/	Compton et al; "Synth	esis and pharmaco lelta8 delta9- and	ological evalua delta9,11-tet				
/KS/	Consroe P, Musty R, R smoked cannabis on p 44-48. (abstract only	Rein J, Tillery W, Poatents with multipl	ertwee R; "The sclerosis"; f	ne perceived effects of Eur. Neurol. (1997) 38-			
/KS/	Coxon et al; "Derivativ (1970) (abstract only)					
/KS/	Crawley et al; "Ananda receptor, induces hypo Pharmacology Bioche	omotility and hypotl mistry and Behavio	hermia in vivo er; vol. 46; 96	o in rodents"; 7-972; 1993			
/KS/	Bioorg. & Med. Chem.	Lett., 1996, 6(1), 1	17-22	cannabinoid mimetics";			
/KS/	*** D'Amour F.E. et al; J. Pharmacol. Exp. Th	"A Method For De er.; 72; 74-79; 194	termining Los 1	ss Of Pain Sensation";			
/KS/	Demuynck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract						

INFORMA	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al		
APPLICA		Novel Pyrazole Ana	alogs Acting on	Cannabinoid Receptors		
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US		
/KS/	anandamide inhibits h Acad. Sci. USA (July	numan breast canc 1998) 95:8375-838	er cell prolifer 80.			
/KS/	Desarnaud F., Cadas H., Piomelli D.; "Anandamide amidohydrolase activity in rat brain microsomes"; J. Biol. Chem.; 270; 6030-6035; (1995)					
/KS/	Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRCA9; ISSN:0006-291X; XP002040933					
/KS/	Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993					
/KS/	Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). (abstract only)					
/KS/	Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528.					
/KS/	the endogenous cann 454. (abstract only)	cellis, L., "Interaction abinoid system"; F	ons between s EBS Letters;	ynthetic vanilloids and (1998); 437(3); 449-		
/KS/	with Alternative Proce only)	dures, Brain Res.,	226, 107 - 11			
/KS/	344-346; (1977)	•		"; J. Org. Chem. 42(2);		
· /KS/	41(19); 3596-3608 (19	998)		s"; J. Med. Chem.; vol.		
/KS/	Edery et al; "Activity o Chem.; 27; 1370-1373	3 (1984)				
/KS/	Eissenstat et al; "Amir cannabinoid mimetics 3105; XP 000651090					
/KS/	Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl-Δ9-Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941					

٠.,

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/790,498 Inventor Alexandros Makriyannis et al Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors Filing Date Group Art Unit Docket No. 1614 UCONAP/226/US		
Fahrenholtz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111			ta eight-	
/KS/	Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 (abstract only)			
/KS/	Fride, E. & Mechoular receptor agonist, anal Pharmacology, vol. 23	ndamide, a brain c	onstituent"; Et	
/KS/	Galiegue S et al.; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. (abstract only)			ppopulations"; Eur J
/KS/	Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194			
/KS/	Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992			
/KS/	Green K.; "Marijuana smoking vs. cannabinoids for glaucoma therapy."; Arch. Ophthamol. (1998) Nov. 116(11); 1433-1437. (abstract only)			
/KS/	Hampson, A.J., Grimaldi M. Axpirod J. Wink D; "Cannabidiol and (-) Δ9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273.			
/KS/	Hanus et al; "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor"; Journal of medicinal Chemistry; 36(20); 3032-3034; 1993			
/KS/	Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) (abstract only)			
/KS/	*** Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391.			1
/KS/	Herzberg U, Eliav E, E WIN 55,212-2 mesyla neuropathic pain"; Nei	te, a high affinity ca	annabinoid ag	onist in a rat model of

INFORMATION DISCLOSURE		Application No. 10/790,498	Inventor Alexandros	Makriyannis et al
APPLICA		Novel Pyrazole Analogs Acting on Cannabinoid Receptors		
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US
/KS/	"Accumulation of N-A	nd, W. S., Jarrahian W., Campbell, W. B; rachidonoylethanolamine (Anandamide) into ells Occurs via Facilitated Diffusion"; Journal of 631-638 (1997)		
/KS/	Horrevoets A.J.G et a phospholipase A by the Biochem.; 198; 247-2	ne affinity label hex		
/KS/	Horrevoets A.J.G et a			scherichia coli outer peptides results in an
	increased reactivity to Eur. J. Biochem.; 198	wards the affinity la		
/KS/	*1* Howlett et al; "Azido and isothicyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal			
/KS/	Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990			
/KS/	Huffman et al; "3-(1',1'-dimethylbutyl)deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999)			
/KS/	Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995)			
/KS/	Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997)			
/KS/	Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic & Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230			
/KS/	Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086			
/KS/	Joy JE, Wagtson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999). (abstract only)			
/KS/	Kaminski NE; "Regula immune function by ca 15;83(1-2):124-32			

INFORMATION DISCLOSURE		Application No. 10/790,498	Inventor Alexandros	Makriyannis et al
APPLICA		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors		
	·	Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US
/KS/	Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989			
/KS/	P., Makriyannis A.; "H	Khanolkar A., Abadji V., Lin S., Hill W., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A.; "Head group analogues of arachidonylethanolamide, the endogenous cannabinoid ligand"; J. Med. Chem.; vol. 39(22); 4515-4519;		
/KS/				d receptors"; Chemistry
/KS/	Exp Biol Med. 2000 O	ct; 225(1):1-8; (ab	stract only)	ne network"; Proc Soc
/KS/	Klein TW et al, "Cann 1998 Aug; 19(8):373-	81		· ·
/KS/		Koutek B. et al; "Inhibitors of arachidonyl ethanolamide hydrolysis"; J. Biol. Chem.; 269(37); 22937-40; 1994; CODEN: JBCHA3; ISSN: 0021-9258;		
/KS/	Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; Anesthesia, 2001, 56: 1059-1068 (abstract only)			
/KS/	*1* Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; J. Med. Chem.; vol. 42(4); 769-776; (1999)			
/KS/	Lang, W. et al; "Subst Microsomal Anandam 902; (1999)			
/KS/	Lavalle et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; J. Org. Chem.; vol. 51(8); 1362-1365; (1986)			
/KS/	Lin S., Khanolkar A., F Makriyannis A.; "Nove (anandamide): affinitie Metabolic Stability"; J.	el Analogues of araces for the CB1 and Med. Chem.; vol.	chidonylethar CB2 Cannabi 41; 5353; 199	nolamide inoid Receptors and 88
/KS/	Loev, B., Bender, P. E "Cannabinoids. Structo Derivatives"; J. Med. C	ure-Activity Studies	Related to 1	,2-Dimethylheptyl
/KS/	Lozinskii, M.O., Bodna Atovmyan, L.O.; "Unus oxalic acid ethyl ester" Khimicheskaya; 11; 26	ar, V.N., Konovalikh sual transformation '; Izvestiya Akadem	nin, S.V., D'ya s of arylhydra nii Nauk SSSr	chenko, O.A., azonoyl chlorides of

INFORM	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al	
CITATION IN AN APPLICATION		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors			
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US	
/KS/	Ludt, R.E. et al; "A co lithium diisopropylami Chem.; 38(9); 1668-1	de in the metalatio	•	of n-butyllithium and lkyltouamides"; J. Org.	
/KS/	*** Maccarron M., End Hormones 2002;65:2	2 5 -255			
/KS/	Mackie K., Devane W cannabinoid, inhibits on neuroblastoma cells";	calcium currents as	a partial ago	nist in N18	
/KS/	*** Markwell, M.A.K., modification of the Lo membrane and lipopro	wry procedure to s	implify proteir	determination in the	
/KS/	Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991				
/KS/	Martyn CN. Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579.				
/KS/	Matsumoto et al; "Cannabinoids 1.1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825				
/KS/	Maurer M, Henn V, Dittrich A, Hofmann A.; "Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial."; Eur. Arch. Psychiát. Clin. Neurosci. (1990), 240:1-4. (abstract only)				
/KS/	Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; Biochimica et Biophysica Acta; vol 1281(2); 1996; XP002111823				
/KS/	Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980)				
/KS/	Mechoulam et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667				
/KS/	Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) (abstract only)				
/KS/	enantiomers of a tetra 1: 315-318; (1990)	*** Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative."; Tetrahedron Asymmetry;			
/KS/	*** Mechoulam, "Cann	abinoids as therap	eutic agents"	; CRC press, 1986	

	ATION DISCLOSURE	Application No. 10/790,498	Inventor Alexandros	Makriyannis et al
CITATIOI APPLICA		Title Novel Pyrazole Analogs Acting on Cannabinoid Recept		Cannabinoid Receptors
		Filing Date 03/01/2004	Group Art Unit	Docket No. UCONAP/226/US
/KS/	*1* Mechoulam et al Progress in Medicin			•
/KS/	Melck, D., Bisogno, T., DePetrocellis, L., Chuang, H., Julius, D., Bifulco, M., DiMarzo, V.; "Unsaturated Long-Chain N-Acyl-vanillyl-amides"; Biochemical and Biophysical Res. Commun.; (1999); 262(1); 275-284 (abstract only).			
/KS/	Meltzer et al; "An imp Synthesis; 1981:985	roved synthesis of (1981)	cannabinol a	nd cannabiorcol";
/KS/	Cannabinoids Cannal	Melvin et al; "Structure-Activity Relationships Defining the ACD-Tricyclic Cannabinoids Cannabinoid Receptor Binding and Analgesic Activity"; Drug Design and Discovery; 13(2); 155-166 (1995). (abstract only)		
/KS/	and analgesic activity	Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993). (abstract only)		
/KS/	Merck Index; 11th edi 1989			
/KS/	*** Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).			
/KS/	*** Morris, S,; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427			
/KS/	Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. (abstract only)			
/KS/	Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM.; "Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol." Am. J. Psychiat.; (1999); 156(3); 495.			
/KS/	*** Nahas G, Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ			
/KS/	Neunhoeffer O., Gottschlich R.; "Acylating activity of O-acylated hydroxylamine derivatives"; Justus Liebigs Ann. Chem.; 736; 100-109; 1970; in German with English abstract			
/KS/	Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) (abstract only)			
/KS/	Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985			

INFORMATION DISCLOSURE		Application No. 10/790,498	Inventor Alexandros	Makriyannis et al
CITATIOI APPLICA		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors		
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US
/KS/	*1* Pacheco M, et al Protein-Linked Rece pp. 170-183 and 172	ptors"; J. Pharma Table (1991).	col. Exp. Th	er.; vol. 257, no. 1,
/KS/	Palmer et al; "Natural Activity Relationships" (2000)			ds and Their Structure- n; 6; 1381-1397;
/KS/	Papahatjis et al; "A ne conformationally cons (2001)			
/KS/	Papahatjis et al; "Pha multiple bond and C1" Chem.; 41(7); 1195-1	-substituted delta8		annabinoid side chains: innabinols"; J. Med.
/KS/	Pertwee et al; "AM630 Sci. 1995, 56(23/24),			eptor agonist"; Life
/KS/	Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044			
/KS/	Pertwee et al; "Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine"; Br. J. Pharmacol.; 105(4); 980-984 (1992). (abstract only)			
/KS/	Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; Pharmacol. Ther., vol. 74(2); pp129-180; (1997); XP002226467			
/KS/	Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; ".alpha.,.betaunsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethynyl)tellurolates with C-ethoxycarbonyl-N-Phenylnitrilimine"; Zhurnal Organicheskoi Khimii; 29(7); 1372-1378; (1993) (abstract only)			
/KS/	*** Pinnegan-Ling D, Musty R.; Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53.			
/KS/	Pinto et al; Cannabino	Pinto et al; Cannabinoid Receptor Binding and Agonist Activity of Amides and Esters of Arachidonic Acid; Mol. Pharmacol.; 1994; 46(3); 516-522.		
/KS/	Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xiw X-Q., Makriyannis A.; "Structural determinants for recognition and translocation by the anandamide transporter"; Proc. Natl. Acad. Sci. USA; 96; 5802-5807; (1999)			
/KS/	Pitt et al; "The synthes labelled cannabinoids' 575; 1975; XP002123	'; Journal of Labelll	arbon-14 and ed Compoun	carrier free tritium ds; vol. 11(4); 551-

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/790,498	Inventor Alexandros	Makriyannis et al
		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors		
1 • • • • • • • • • • • • • • • • • • •			Group Art Unit 1614	Docket No. UCONAP/226/US
	Porreca F., Mosberg	The state of the s	•	
/KS/	delta and kappa opiod receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; J. Pharmacol. Exp. Ther.; 230(2); 341-348; (1994). (abstract only)			
/KS/	Razdan et al; "Drugs analogues of dimethy 1976 (abstract only)	derived from canna	abinoids. 6S	Synthesis of cyclic
/KS/	Razdan et al; "Pharma Anandamide Analogs	"; Life Sci.; 1995; 5	6(23-24); 204	11-2048
/KS/	Reggio et al; "Charac cannabinoid receptor United States; vol. 36	using the active ar	alog approac	
/KS/	Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcyclase"; J. Med. Chem. 1997, 40(20); 3228-3233			
/KS/	Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414. (abstract only)			
/KS/	Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of a spinal cannabinoids"; Eur. J. Pharmacol. (1998) 346:145-153.			
/KS/	Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors"; Pain (1998) 75:111-119.			
/KS/	*1* Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995)			
/KS/	*1* Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994)			
/KS/	Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989			
/KS/	Santus, Maria; "Studie of the derivatives of 1, 3); 183-188; 1993 (ab	,2,4,5-tetrazine"; Ao stract only)	cta Polonae P	Pharmaceutica; 50(2-
/KS/	Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/790,498 Title Novel Pyrazole Ana		Makriyannis et al
		Filing Date 03/01/2004	Group Art Unit 1614	Docket No. UCONAP/226/US
/KS/	*** Schuel, H., Burkm Cannabinoid receptor	s in human sperm.	Mol. Biol. Ce	ell., (1997) (8), 325a.
/KS/	Serdarevich B., Carol monoglycerides of an	teiso fatty acids"; J	. Lipid Res.;	7; 277-284; (1966)
/KS/	Shawali, A.S., Albar, I of N-aryl-C-ethoxycar Of Chemistry; 64(5); 8	bonyl formohydrazi	doyl chloride	of dehydrochlorination s"; Canadian Journal
/KS/	Shen M. Thayer SA: (hippocampal neurons 462.	-	•	
/KS/	Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407			
/KS/	Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771			
/KS/	Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands""; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918			
/KS/	Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. (abstract only)			
/KS/	Smith P.B. et al; "The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice"; Journal of Pharmacology and Experimental Therapeutics; vol. 270(1):219-227; 1994			
/KS/	Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172 (abstract only)			
/KS/	*1* Tetko, I. V. et al; "Volume Learning Algoritm Artificial Neural Networks For 3D QSAR Studies"; J. Med. Chem.; vol. 44, no. 15 (2001) pp. 2411-2420, 2413, 2414 Table 1.			
/KS/	Tius et al; "Conformat Steroeselective synthe (1994) (abstract only	esis and activity"; T		-

INFORMATION DISCLOSURE		Application No. Inventor Alexandros Makriyannis et al		
CITATIO APPLICA		Title Novel Pyrazole Analogs Acting on Cannabinoid Receptors		
		Filing Date 03/01/2004	Group Art Unit	Docket No. UCONAP/226/US
/KS/	Twitchell, W. et al; "Ca in cultured rat hippoca 50; 1997 (abstract on	mpal neurons"; J ly)	ournal of Neur	ophysiology; 78(1); 43
/KS/	Ueda, N., Endocannal Mediators 2002;68-69			ns & Other Lipid
/KS/	Vogel Z., Barg J., Levy "Anandamide, a brain cannabinoid receptors 352-355; (1993) (abst	endogenous con and inhibits ade ract only)	npound, interac nylate cyclase"	cts specifically with '; J. Neurochem.; 61(1
/KS/	Wagner JA, Varga K, oby Endothelia Ananda	mide Receptors";	Hypertension	(1999) 33:429-434.
/KS/	Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; Synlett 1992, 207-210			
/KS/	Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; J. Pharmacol. Exp. Ther. 1998, 285(3), 995-1004; XP-001097982			
/KS/	Wilson et al; "9-nor-de intersts"; J. Med. Chen			nnabinoid of metabolic
/KS/	Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; J. Med. Chem.; 18(7); 700-703; (1975)			
/KS/	Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; J. Med. Chem.; 19(9); 1165-1167; (1976)			
/KS/	Yamada et al; "(Aminoalkyl)indole isothiocyanates as potentiual electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974			
/KS/	Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol; a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994)			
/KS/	Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994)			
Examiner	/Kamal Saeed/	Date Considered	05/28/2007	